Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Weijuan Li, Kevin Croce, David P. Steensma, et al.
Journal of the American College of Cardiology (2015) Vol. 66, Iss. 10, pp. 1160-1178
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 3031
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, et al.
Journal of the National Comprehensive Cancer Network (2018) Vol. 16, Iss. 3, pp. 310-320
Open Access | Times Cited: 1597
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1556
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. e263-e421
Open Access | Times Cited: 1516
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano, Daniel J. Lenihan, Michael G. Fradley, et al.
Annals of Oncology (2020) Vol. 31, Iss. 2, pp. 171-190
Open Access | Times Cited: 807
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Giuseppe Curigliano, Daniela Cardinale, Susan Dent, et al.
CA A Cancer Journal for Clinicians (2016) Vol. 66, Iss. 4, pp. 309-325
Open Access | Times Cited: 654
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
New England Journal of Medicine (2016) Vol. 375, Iss. 15, pp. 1457-1467
Closed Access | Times Cited: 554
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Arun Sharma, Paul W. Burridge, Wesley L. McKeithan, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 377
Open Access | Times Cited: 357
Myocarditis in the Setting of Cancer Therapeutics
Marc P. Bonaca, Benjamin A. Olenchock, Joe‐Elie Salem, et al.
Circulation (2019) Vol. 140, Iss. 1, pp. 80-91
Open Access | Times Cited: 352
Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease
Arvind K. Pandey, Eric K. Singhi, Juan Pablo Arroyo, et al.
Hypertension (2017) Vol. 71, Iss. 2
Open Access | Times Cited: 269
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
Joachim Alexandre, Jennifer Cautela, Stéphane Éderhy, et al.
Journal of the American Heart Association (2020) Vol. 9, Iss. 18
Open Access | Times Cited: 236
Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis
MacRae F. Linton, Javid J. Moslehi, Vladimir R. Babaev
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 11, pp. 2703-2703
Open Access | Times Cited: 215
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 10, pp. e333-e465
Open Access | Times Cited: 210
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
Matthias Totzeck, Martin Schüler, Martin Stuschke, et al.
International Journal of Cardiology (2019) Vol. 280, pp. 163-175
Closed Access | Times Cited: 185
Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention
Saro H. Armenian, Gregory T. Armstrong, Gregory J. Aune, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 21, pp. 2135-2144
Open Access | Times Cited: 181
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Crystal S. Denlinger, Tara Sanft, K. Scott Baker, et al.
Journal of the National Comprehensive Cancer Network (2018) Vol. 16, Iss. 10, pp. 1216-1247
Open Access | Times Cited: 178
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival
Jonathan Douxfils, Hélène Haguet, François Mullier, et al.
JAMA Oncology (2016) Vol. 2, Iss. 5, pp. 625-625
Open Access | Times Cited: 172
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association
Umberto Campia, Javid J. Moslehi, Laleh Amiri‐Kordestani, et al.
Circulation (2019) Vol. 139, Iss. 13
Open Access | Times Cited: 170
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Javid J. Moslehi, Andrew H. Lichtman, Arlene H. Sharpe, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 5
Open Access | Times Cited: 146
Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers
Giancarlo Trimarchi, Lucio Teresi, Roberto Licordari, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1051-1051
Open Access | Times Cited: 19
Multiparametric MRI for characterization of the tumour microenvironment
Emily Hoffmann, Max Masthoff, Wolfgang G. Kunz, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 428-448
Closed Access | Times Cited: 16
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer, Ronald K. Knickerbocker, Michele Baccarani, et al.
Leukemia Research (2016) Vol. 48, pp. 84-91
Open Access | Times Cited: 148
Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia
Suzanne D. Burke, Zsuzsanna K. Zsengellér, Eliyahu V. Khankin, et al.
Journal of Clinical Investigation (2016) Vol. 126, Iss. 7, pp. 2561-2574
Open Access | Times Cited: 128
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
Joachim Alexandre, Javid J. Moslehi, Kevin Bersell, et al.
Pharmacology & Therapeutics (2018) Vol. 189, pp. 89-103
Closed Access | Times Cited: 124
Oncocardiology—Past, Present, and Future
Edward T.H. Yeh, Hui‐Ming Chang
JAMA Cardiology (2016) Vol. 1, Iss. 9, pp. 1066-1066
Open Access | Times Cited: 115
Page 1 - Next Page

Scroll to top